This brochure outlines its main objectives and pillars of work. If you are interested in joining HYPER or learning more, please contact Luca Deplano, Associate Manager, Innovation Policy.
Read more
Vaccines are one of the most effective and cost-efficient medical technologies ever developed. Except for clean water, nothing has had a larger effect on global health than vaccines, especially for children.
Read moreOn World Intellectual Property (IP) Day, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the World Intellectual Property Organization (WIPO) co-organized an event on ‘Innovating for Better Health: Supporting Young Innovators Through IP’, celebrating the young people who are innovating to shape health progress across the world, and particularly in Africa.
Read moreWe must make up ground lost in the fight against malaria during the COVID-19 pandemic. Innovation in vaccines and treatment offer hope for solutions.
Read moreThank you again for joining us for this media briefing that will give you a snapshot of what biopharmaceutical companies continue to innovate and manufacture in response to the pandemic. Already last year, we were telling policy makers that supplies of COVID-19 vaccines were fast out-stripping demand. We ended 2021 with over 11 billion vaccines...
Read moreOrganized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) – representing the global innovative biopharmaceutical industry committed to addressing the novel coronavirus public health crisis.
Read more
To date, over 13 billion doses of COVID-19 vaccines have been produced and 11 billion have been administered. Presently, vaccine supplies outstrip global demand, with voluntary technology transfer playing a significant role. Urgent steps are needed to provide a high level of protection against COVID-19 among the elderly and vulnerable populations wherever they live. Several...
Read moreJoint Guidance on Virtual and Hybrid International Medical Congresses by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA)
Read more
The biopharmaceutical industry is committed to working with stakeholders to improve pandemic preparedness for the future and to ensure equitable access to medical countermeasures. Any system should be built on what worked well during the COVID-19 pandemic with robust IP frameworks enabling collaborations, as well as immediate sharing of pathogens. As the INB enters deeper...
Read moreHosted within the DIA Europe 2022 meeting (29-31 March 2022) under the Regional Updates Track, IFPMA and its Africa Regulatory Network organized a virtual panel discussion on “The new African Medicines Agency (AMA): Accelerating Regulatory System Strengthening in Africa.” The session gathered global health experts across government, civil society, and industry to discuss progress made...
Read more
Geneva, April 12 2022 – Commenting on the publication of draft guidance from the National Institute for Health and Care Excellence (NICE) on antimicrobial drugs to become available as part of the UK’s innovative ‘subscription-type’ payment model, Thomas Cueni, IFPMA Director-General, said: “We welcome the results of the UK work to reward the full value...
Read moreApril 4, 2022, Geneva – The international trade body representing the biopharmaceutical industry (IFPMA) today welcomes the announcement of the AMR Action Fund’s first portfolio investments. The Fund is the world’s largest public-private partnership investing in biotech companies that are developing antibiotics, involving more than 20 leading biopharmaceutical companies who raised the majority of the...
Read more